Seed-round investor in Rgenta Therapeutics, an RNA-targeted small-molecule drug discovery company, which went on to raise a $52M Series A led by AstraZeneca's healthcare fund.
Rgenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative RNA-targeting oral small molecules to treat incurable diseases, particularly in oncology and CNS disorders
Rgenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative RNA-targeting oral small molecules to treat incurable diseases, particularly in oncology and CNS disorders.